Wayne Kuznar

Articles

TKI Discontinuation Criteria Established in Updated NCCN CML Guideline

March 23rd 2019

With careful monitoring, discontinuation of TKI therapy is considered safe in adult patients with chronic myeloid leukemia in the chronic phase, who achieve and maintain a major molecular response.

Frontline Combos Poised to Change NCCN Guidelines in Advanced RCC

March 22nd 2019

The 2019 National Comprehensive Cancer Network guideline on the management of advanced clear cell renal cell carcinoma undergoes a major shift in risk category used to define preferred and alternative first-line treatments.

Pembrolizumab Shows Promising Activity in Non-Clear Cell RCC

February 18th 2019

Single-agent pembrolizumab (Keytruda) showed encouraging antitumor activity as first-line treatment in patients with non-clear cell renal cell carcinoma, especially in those with papillary or unclassified histology.

Modest Activity With Durvalumab/Savolitinib Combo in Papillary RCC Not Enough to Warrant Further Studies

February 17th 2019

The overall response rate achieved with with the combination of savolitinib and durvalumabin in patients with metastatic papillary renal cell carcinoma in the phase II CALYPSO study did not meet the prespecified criterion for further investigation of the regimen.

Pembrolizumab/Cabozantinib Combo Is Well Tolerated, Shows Activity in Metastatic RCC

February 17th 2019

The combination of pembrolizumab (Keytruda) and cabozantinib (Cabometyx) has antitumor activity in patients with previously treated metastatic renal cell carcinoma and is tolerated at their separate approved doses for this indication.

Sacituzumab Govitecan Active in Advanced Urothelial Carcinoma

February 16th 2019

Sacituzumab govitecan exhibited significant clinical activity in an open-label, single-arm phase I/II basket study of patients with heavily pretreated, relapsed/refractory metastatic urothelial cancer.

Layered Treatment With Radium-223 and Abiraterone May Reduce Skeletal Events in mCRPC

February 16th 2019

In a real-world setting, patients with metastatic castration-resistant prostate cancer who received radium-223 dichloride with abiraterone acetate in a layered fashion experienced a lower rate of symptomatic skeletal events compared with those who received the treatments concurrently.

Enzalutamide Extends Radiographic PFS in Metastatic Hormone-Sensitive Prostate Cancer

February 16th 2019

The addition of enzalutamide (Xtandi) to androgen deprivation therapy significantly prolonged radiographic progression-free survival compared with ADT alone in men with metastatic hormone-sensitive prostate cancer.

Darolutamide Improves Metastasis-Free Survival in Nonmetastatic CRPC

February 16th 2019

Darolutamide added to androgen deprivation therapy significantly improved metastasis-free survival compared with placebo plus ADT in patients with nonmetastatic castration-resistant prostate cancer enrolled in the phase III ARAMIS trial.

Durvalumab/Tremelimumab Combo Improves Efficacy in Refractory CRC

January 20th 2019

The combination use of durvalumab and tremelimumab plus best supportive care prolonged median overall survival by 2.5 months compared with supportive care alone in patients with advanced refractory colorectal cancer.

Triplet Regimen Shows Durable Responses in BRAF V600E-Mutant Metastatic CRC

January 20th 2019

Clinical outcomes with the combination of encorafenib, binimetinib, and cetuximab exceed historic data in patients with BRAF V600E-mutant metastatic colorectal cancer.

Regorafenib Extends PFS in Locally Advanced Biliary Tract Cancer

January 20th 2019

The oral multi-kinase inhibitor regorafenib extended progression-free survival in patients with metastatic or unresectable biliary tract cancer who were previously treated with gemcitabine and a platinum-based chemotherapy.

Dabrafenib/Trametinib Combo Induces High Responses in BRAF V600E-Mutant Biliary Tract Cancer

January 19th 2019

The combination of dabrafenib and trametinib induced responses in nearly half of patients with BRAF V600E–mutated biliary tract cancer who participated in a phase II basket trial that enrolled patients with BRAF V600E–mutated rare cancers.

SM-88 Achieves Encouraging Clinical Benefit Rate in Metastatic Pancreatic Cancer

January 19th 2019

The novel oral anticancer regimen known as SM-88, which consists of a tyrosine derivative, an mTOR inhibitor, a CYP3a4 inducer, and an oxidative stress catalyst, has promising efficacy with no meaningful toxicity in patients with metastatic pancreatic cancer who have progressed on at least 1 prior line of therapy.

Ramucirumab/Nivolumab Combo Shows Potential in Advanced Gastric Cancer

January 18th 2019

The combination of nivolumab and ramucirumab has activity in patients with previously treated advanced gastric adenocarcinoma, investigators reported at the 2019 Gastrointestinal Cancers Symposium.

Trastuzumab ADCC May Affect Outcomes in HER2+ Breast Cancer

December 28th 2018

Patients with HER2-positive early or locally advanced breast cancer who were exposed to reference trastuzumab lots with a marked downward shift in antibody-dependent cell-mediated cytotoxicity (ADCC) had worse outcomes than those not exposed to at least 1 shifted ADCC lot or those treated with its biosimilar.

Frontline Bendamustine/Rituximab in MCL Improves Real-World EFS Outcomes

December 20th 2018

The frontline induction treatment of bendamustine and rituximab has improved event-free surviva compared with R-CHOP therapy in patients with mantle cell lymphoma.

Biosimilar Filgrastim Would Lower Medicare Out-of-Pocket Expenses

December 19th 2018

Out-of-pocket expenditures are substantially less among Medicare beneficiaries with breast cancer undergoing chemotherapy who receive prophylaxis for febrile neutropenia with a filgrastim biosimilar as opposed to the reference product.

Trastuzumab Biosimilar CT-P6 Shows Comparable Efficacy at 2-Year Follow-up

December 14th 2018

CT-P6, a proposed biosimilar to trastuzumab, exhibited long-term disease-free survival and overall survival similar to the reference product in the treatment of patients with HER2-positive early breast cancer.

Venetoclax Shows Durable Responses in Relapsed/Refractory MCL

December 14th 2018

Single-agent venetoclax (Venclexta) led to durable responses in patients with relapsed/refractory mantle cell lymphoma with a low rate of late-onset toxicities.